Skip to main content
Premium Trial:

Request an Annual Quote

GNS Healthcare Nets SAIC Contract to Analyze NCI's Drug Interaction Data

Premium

GNS Healthcare said this week that it has signed a subcontract with SAIC-Frederick to create in silico simulations of drug interaction data generated by applying several well-known cancer treatments to the National Cancer Institute's NCI-60 cancer cell line panel.

Financial terms of the agreement were not disclosed.

GNS said that in the first phase of the project, it will use its Reverse Engineering and Forward Simulation platform to build computer models from transcriptional profiling data previously collected by NCI from the application of several drugs to the panel.

The list of drugs includes doxorubicin X2, Millennium Pharmaceuticals' Velcade (bortezimib), paclitaxel, Bristol-Myers Squibb's Sprycel (dasatinib), Pfizer's Sutent (sunitinib), and Wyeth's Rapamycin.

The simulations are expected to provide insights into key genetic and molecular mechanisms of drug efficacy and resistance in cancer by connecting drug doses to transcriptional networks to endpoints, GNS said.

GNS also plans to build versions of the computer models that may be made available more broadly to cancer scientists for their own research via a web interface.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.